Heron Therapeutics (HRTX) EPS (Weighted Average and Diluted): 2021-2025
Historic EPS (Weighted Average and Diluted) for Heron Therapeutics (HRTX) over the last 5 years, with Sep 2025 value amounting to -$0.10.
- Heron Therapeutics' EPS (Weighted Average and Diluted) fell 233.33% to -$0.10 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.09, marking a year-over-year increase of 43.75%. This contributed to the annual value of -$0.09 for FY2024, which is 88.75% up from last year.
- Heron Therapeutics' EPS (Weighted Average and Diluted) amounted to -$0.10 in Q3 2025, which was down 400.00% from -$0.02 recorded in Q2 2025.
- In the past 5 years, Heron Therapeutics' EPS (Weighted Average and Diluted) registered a high of $0.02 during Q4 2024, and its lowest value of -$0.63 during Q1 2022.
- In the last 3 years, Heron Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$0.05 in 2023 and averaged -$0.09.
- Examining YoY changes over the last 5 years, Heron Therapeutics' EPS (Weighted Average and Diluted) showed a top increase of 150.00% in 2025 and a maximum decrease of 233.33% in 2025.
- Over the past 5 years, Heron Therapeutics' EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.53 in 2021, then skyrocketed by 75.47% to -$0.13 in 2022, then spiked by 61.54% to -$0.05 in 2023, then surged by 140.00% to $0.02 in 2024, then plummeted by 233.33% to -$0.10 in 2025.
- Its last three reported values are -$0.10 in Q3 2025, -$0.02 for Q2 2025, and $0.01 during Q1 2025.